Olaparib: new treatment option for ovarian cancer

Olaparib (Lynparza) is an inhibitor of human poly (ADP-ribose) polymerase enzymes (PARP-1, PARP-2 and PARP-3).

In Europe, ovarian cancer is the fifth most commonly diagnosed cancer in women and the sixth leading cause of cancer death among women. | iStock
In Europe, ovarian cancer is the fifth most commonly diagnosed cancer in women and the sixth leading cause of cancer death among women. | iStock
Lynparza is indicated as monotherapy for patients with relapsed BRCA-mutated high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy.

Pharmacology

Olaparib blocks repair of single-strand DNA breaks by binding to the active site of DNA-associated PARP, preventing the enzyme’s dissociation from the DNA. 

Clinical efficacy

Further information
View Lynparza drug record
Summary of Product Characteristics
Manufacturer: AstraZeneca

Study 19 was a randomised, double-blind, placebo-controlled phase II trial involving 265 patients with serous ovarian cancer, including fallopian tube or primary peritoneal cancer, who had been treated with at least two platinum-containing regimens. A total of 136 patients were assigned to the olaparib group and received 400mg twice daily; the other 129 received placebo.

Progression-free survival was significantly longer with olaparib than with placebo (median 8.4 months vs 4.8 months; hazard ratio for progression or death 0.35, 95% CI 0.25–0.49,  p<0.001). Patients taking olaparib had a lower risk of disease progression regardless of progression-free survival. 

In an interim analysis, overall survival did not differ significantly between patients taking olaparib and those taking placebo (p=0.75)

Adverse effects

Patients in the olaparib group experienced more side-effects than those in the placebo group, most commonly nausea (68%), fatigue (49%), vomiting (32%) and anaemia (17%). 

Eligibility

Preliminary NICE guidance does not recommend funding of Lynparza on the NHS. Treatment can be prescribed privately or for personally funded patients. 
 
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases